Demant sees multiple scenarios for divesting surgical division
However, it’s too soon to speculate in concrete outcomes before authorities finish their evaluations of whether Demant’s divestment of Oticon Medical is anti-competitive, says CEO.
by albert rønning-andersson, translated by daniel pedersen & christian radich hoffman
Danish hearing group Demant’s attempt to divest its surgical division, Oticon Medical, to Australia-based Cochlear is seemingly hanging by a thread.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
